Showing 2644 results
- Featured News /
The RUXCOVID clinical trial highlights the Novartis commitment to leverage our expertise and resources to support the global response to the COVID-19 pandemic.
- Media Library /
- Media Library /
- Media Release /After seven years as President of NIBR and a member of the ECN, Dr. Bradner will pursue a next chapter of scientific contribution and leadership outside of NovartisBuilding on NIBR foundation, Dr.…
- Media Release /Overall survival results from pooled exploratory analysis of MONALEESA trials in patients with aggressive HR+/HER2- advanced breast cancer treated with Kisqali® Data from VISION study reporting…
- Media Release /Approval based on results from pivotal Phase III ASCEMBL trial, in which Scemblix® (asciminib) nearly doubled the major molecular response rate vs. Bosulif®* (bosutinib) (25.5% vs. 13.2%) with a more…
- Key Release /Ad hoc announcement pursuant to Art. 53 LR Sandoz strategic review concludes that a separation of Sandoz by way of a 100% spin-off is in the best interest of shareholders, creating the…
- Media Release /Phase III CANOPY-A trial did not meet primary endpoint of disease-free survival in patients with stages II-IIIA and IIIB completely resected non-small cell lung cancer1Findings will be…
- Media Release /Submission of proposed biosimilar supported by comprehensive package; aims to expand treatment access for people with multiple sclerosis in US and EUMultiple sclerosis (MS) is a chronic inflammatory…
- Media Release /Submission supported by comprehensive analytical data package and clinical Phase I pharmacokinetics bridging study Proposed Hyrimoz® HCF would help expand access to medicine for patients with chronic…
Pagination
- ‹ Previous page
- 1
- …
- 170
- 171
- 172
- 173
- 174
- 175
- 176
- …
- 265
- › Next page